Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gustavo Elias

Vascular & Interventional Radiology Fredericksburg, VA Medical Doctor

NPI 1992063234 CMS profile 1393972

10401 Spotsylvania Ave Ste 203, Fredericksburg, VA 22408

Open in the dashboard

General payments

$8,174

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,765 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Gustavo Elias of Fredericksburg, VA is reported in the CMS Open Payments database as having received $8,174 across 86 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12,765 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 74th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,373 18
2024 General $2,782 20
2023 General $2,779 19
2022 General $512 9
2021 General $392 6
2020 General $122 6
2019 General $214 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gustavo Elias
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Gustavo Elias were reported at $1,373. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Gustavo Elias Vascular & Interventional Radiology median Middle half National median
2019 $214 $422 $125–$1,555 $163
2020 $122 $200 $68–$652 $114
2021 $392 $280 $99–$866 $132
2022 $512 $433 $137–$1,497 $149
2023 $2,779 $506 $152–$2,019 $160
2024 $2,782 $556 $175–$1,930 $164
2025 $1,373 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $4,988 31 payments
  2. Inari Medical, Inc. $821 7 payments
  3. Cook Medical LLC $599 7 payments
  4. Terumo Medical Corporation $417 4 payments
  5. Medtronic, Inc. $326 9 payments
  6. Stryker Corporation $323 3 payments
  7. Boston Scientific Corporation $218 7 payments
  8. Janssen Pharmaceuticals, Inc $98 2 payments
  9. Silk Road Medical, Inc. $88 1 payment
  10. Medtronic Vascular, Inc. $70 3 payments
  11. Other $227 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,109 79 payments
  2. Travel and Lodging $3,066 7 payments
Products named General payments · program years 2019–2025
  1. Indigo System $4,687 26 payments
  2. FLOWTRIEVER CATHETER, S $1,032 9 payments
  3. CT THROMBECTOMY SYSTEM KIT $1,032 9 payments
  4. Azur CX Detachable $421 4 payments
  5. ANGIO-SEAL $417 4 payments
  6. RUBY Coil $238 2 payments
  7. ZILVER PTX $203 3 payments
  8. Abre $196 3 payments
  9. HydroPearl $148 1 payment
  10. ZILVER VENA $121 1 payment
  11. Other $1,223 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 207 billing codes

Paid by Medicare

$222,193

Of which drugs: $1,676

Medicare patients

1,194

Average age 75

Services billed

14,461

640 women, 554 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 45%
Diabetes 41%
Chronic kidney disease 38%
Heart failure 31%
Atrial fibrillation 31%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 119 11,766 $1,177
Injection, fentanyl citrate, 0.1 mg J3010 Office 17 341 $259
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 226 $172
Injection, cefazolin sodium, 500 mg J0690 Office 15 50 $31
Injection, midazolam hydrochloride, per 1 mg J2250 Office 18 56 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record